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abstract
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in
combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of
combination palbociclib plus letrozole as neoadjuvant therapy.
PATIENTS AND METHODS Postmenopausal women with ER-positive primary BC and tumors greater than or equal to
2.0 cmwere randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib
plus letrozole to 14weeks (B); palbociclib for 2weeks, then palbociclib plus letrozole to 14weeks (C); or palbociclib plus
letrozole for 14 weeks. Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule. Core-cut
biopsies were taken at baseline and 2 and 14weeks. Coprimary end points for letrozole versus palbociclib plus letrozole
groups (A v B + C + D) were change in Ki-67 (protein encoded by the MKI67 gene; immunohistochemistry) between
baseline and 14 weeks and clinical response (ordinal and ultrasound) after 14 weeks. Complete cell-cycle arrest was
deﬁned as Ki-67 less than or equal to 2.7%. Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase.
RESULTS Three hundred seven patients were recruited. Clinical response was not signiﬁcantly different between
palbociclib plus letrozole and letrozole groups (P = .20; complete response + partial response, 54.3% v 49.5%),
and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with
palbociclib plus letrozole compared with letrozole (24.1 v 22.2; P , .001) in the 190 evaluable patients
(61.9%), corresponding to a geometric mean change of297.4% versus288.5%. More patients on palbociclib
plus letrozole achieved complete cell-cycle arrest (90% v 59%; P , .001). Median log-fold change (sup-
pression) of cleaved poly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole
(20.80 v20.42; P, .001). More patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v
17.0%; P , .001) mainly because of asymptomatic neutropenia.
CONCLUSION Adding palbociclib to letrozole signiﬁcantly enhanced the suppression of malignant cell pro-
liferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which
was possibly related to a concurrent reduction in apoptosis.
J Clin Oncol 37:178-189. © 2018 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Use of endocrine therapy for the treatment of hormone
receptor (HR) –positive breast cancer (BC) is a semi-
nal example of successfully targeted cancer treatment.
Nonetheless, endocrine therapy resistance, either de
novo or acquired, remains a challenge in patients with
both early and advanced BC.1-4 One approach to re-
verse resistance to standard endocrine therapy has
been to target an alternative pathway.
Cyclin-dependent kinases CDK4 and CDK6 promote
progression from G1 phase to S phase of the cell
cycle. Inhibition of these kinases leads to decreased
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proliferation of estrogen receptor (ER) –positive tumors
and reverses endocrine resistance in some patients. The
CDK4/6 inhibitor, palbociclib (Ibrance; Pﬁzer, New York,
NY), has demonstrated considerable activity when com-
bined with other endocrine therapies in patients with
metastatic BC in both ﬁrst-line and second-line settings,5-8
with recent results demonstrating prolonged overall
survival in the second-line setting.9 Large, phase III ad-
juvant BC trials with palbociclib and other CDK4/6 in-
hibitors are ongoing [PALLAS (ClinicalTrials.gov identiﬁer:
NCT02513394) PENELOPE-B (ClinicalTrials.gov identi-
ﬁer: NCT01864746), andMONARCH-E (ClinicalTrials.gov
identiﬁer: NCT03155997).
In early BC, use of neoadjuvant therapy is an attractive
option to facilitate breast conservation and, critically,
enables the assessment of in vivo biomarkers to identify
proof-of-principle activity or predict responsive or resis-
tant subgroups of tumors.10,11 Achievement of a pathologic
complete response (pCR) in HR-positive cancers to che-
motherapy is less common than in other subtypes of BC. A
recent meta-analysis reported similar clinical responses
and achievement of breast conservation in HR-positive BC
with neoadjuvant endocrine therapy compared with com-
bination chemotherapy, but with lower toxicity.12 As such,
strategies to further improve response to neoadjuvant en-
docrine therapy in HR-positive cancers are more relevant
than using chemotherapy. In HR-positive disease, a decrease
in the proliferation marker Ki-67 (protein encoded by the
MKI67 gene) from baseline in response to endocrine
therapy has been validated as a marker of treatment beneﬁt,
with measurement of Ki-67 after 2 weeks of endocrine
therapy shown to improve the prediction of recurrence-free
survival (RFS).13,14 Given the predominantly antiproliferative
effects of palbociclib, suppression of Ki-67 is a rational end
point for estimating whether there is efﬁcacy with the ad-
dition of palbociclib to an aromatase inhibitor (AI) versus AI
alone in the neoadjuvant setting.
Here, we report the results of PALLET, a large, multinational,
neoadjuvant randomized trial (ClinicalTrials.gov identiﬁer:
NCT02296801, ISRCTN31243262), designed with copri-
mary end points examining the biologic and clinical effects
of neoadjuvant letrozole with or without palbociclib for
14 weeks as primary treatment of ER-positive/human
epidermal growth factor receptor 2 (HER2) –negative
early invasive BC.
PATIENTS AND METHODS
Full details of the methodology are available in the Data
Supplement.
Trial Design and Patients
PALLET is a phase II randomized multicenter trial with
parallel United Kingdom and North American protocols.
Patients were recruited from 38 sites in the United
Kingdom, United States, and Canada. Eligible patients
were postmenopausal womenwith unilateral, operable, ER-
positive, HER2-negative tumors that measured at least
2 cm by ultrasound with no evidence of metastatic disease.
ER positivity and HER2 negativity were deﬁned as per
ASCO/College of American Pathologists guidelines15,16 and
were locally assessed.
Patients were randomly assigned 3:2:2:2 to one of four
treatment groups. Group A received letrozole alone for
14 weeks, group B letrozole for 2 weeks followed by pal-
bociclib plus letrozole to 14 weeks, group C palbociclib for
2 weeks followed by palbociclib plus letrozole to 14 weeks,
and group D palbociclib plus letrozole for 14 weeks (Data
Supplement). The parallel four-group design with a 2-week
change for groups B and C allowed us to assess the role
of each drug alone or in combination in the suppression of
Ki-67. Ki-67 was centrally assessed. Treatment allocation
was performed by computer-generated random permuted
blocks and stratiﬁed by geographic location—United Kingdom
versus North America (United States and Canada; Data
Supplement). Letrozole 2.5 mg/d was administered orally
continually and palbociclib 125 mg/d was administered
orally on a 21-days-on, 7-days-off schedule. Protocol-
speciﬁed dose modiﬁcations for palbociclib were recom-
mended for various adverse events.
Procedures
After randomization, patients visited the clinic each week
for the ﬁrst 4 weeks, then every other week until week 14.
Follow-up visits were at 30 days post-trial treatment and
12 months after random assignment. Assessments re-
quired at these visits are described in the protocol.
Core-cut biopsies and trial-speciﬁc blood samples were
taken at baseline (post–random assignment), 2 weeks
(before commencement of second drug for groups B and
C), and 14 weeks or at the discontinuation of study therapy
(within 48 hours of the last dose of trial treatment).
Outcomes
Principal outcome analyses focused on changes between
baseline and the end of treatment (EoT) and compared
letrozole (A) with palbociclib plus letrozole (B + C + D).
Coprimary end points were clinical response (ultrasound;
Eastern Cooperative Oncology Group17) and (ii) change in
the proliferation marker Ki-67 (immunohistochemistry).
Secondary end points included pCR, changes in sur-
gical intent, and safety. In addition, changes in Ki-67
between baseline and week 2 and week 2 to EoT were
compared in groups for which treatment differed during
each respective time period. Prespeciﬁed exploratory
biomarkers included cleaved poly (ADP-ribose) poly-
merase (c-PARP; apoptosis).
Statistical Analysis
The PALLET trial was powered (90%) using a conventional
comparative design with alpha (a = 5% overall) split be-
tween the two coprimary end points. Improved clinical
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response would be detected for palbociclib plus letrozole
over letrozole (complete response: 31% v 21%; partial
response: 57% v 54%; stable disease: 5% v 15%; pro-
gressive disease: 2% v 5%) with 284 patients (a = 4% and
90% power). With a 5% nonevaluable rate and 3:2:2:2 al-
location, the recruitment target was 306 patients. Improve-
ment with decreased Ki-67 from 80% in group A to 90% in
groups B plus C plus D (log-fold change of20.693; standard
deviation of 1.5) would be detected with 279 patients with
a = 1% and 90% power. Interim analyses were planned at
25%and50%of trial end point information, and the trial would
have been terminated for futility at the second analysis if there
was no evidence that either end point favored palbociclib.
Post hoc analysis revealed that there were 279 evaluable
clinical responses (93:186), which under the initial sample
size speciﬁcations would give 88.1% power. Log-fold
changes in Ki-67 were available for 190 patients (61.9%;
65:125) to provide 75% power.
All patients were analyzed according to the intention
to treat approach. Clinical response was treated as an
ordinal outcome and compared using the Mann-Whitney
test in all patients with Eastern Cooperative Oncology
Group response data available at EoT. Changes in Ki-67
and c-PARP were analyzed on the natural log-fold scale
in patients with biopsy data available at both baseline
and EoT. As an exploratory analysis, complete cell cycle
arrest (CCCA) at EoT (deﬁned as Ki-67 of 2.7% or less)
was compared between groups using a logistic regres-
sion model that adjusted for recruitment region and
histologic type.
RESULTS
Between February 27, 2015, andMarch 8, 2018, 307women
were recruited—166 from the United Kingdom (Data Sup-
plement) and 141 from North America (Data Supplement;
group A, n = 103; group B, n = 68; group C, n = 69; group D,
n = 67; Fig 1). Baseline demographic and clinical charac-
teristics were similar across treatment groups (Table 1).
Overall, 253 patients (82.4%) completed 14 weeks of
treatment. In the letrozole group (A) this was 85% (n = 88)
compared with 81% (n = 165) of patients who received
palbociclib plus letrozole (B + C + D). The median per-
centage of scheduled letrozole received was 99% in all
treatment groups. The median [interquartile range (IQR)]
percentages of the scheduled dose of palbociclib received in
groups B, C, and D were 99.2% (82.9% to 100.0%), 90.9%
(67.8% to 100.0%), and 97.4% (79.2% to 100.0%), re-
spectively. Palbociclib was interrupted/delayed in 21.6% of
patients (n = 44), dose was reduced in 2.0% of patients (n =
4), and treatment was interrupted/delayed and dose re-
duced in 15.2% of patients (n = 31; Data Supplement).
Clinical response outcomes at EoT were available for 279
patients (90.8%; Table 2). In the letrozole group (A), 46
Randomly assigned
(N = 307)
3:2:2:2
Group A: Letrozole alone
(n = 103)
(n = 100)
(n = 4)
(n = 2)
(n = 1)
Group B: Letrozole to week 2,
followed by palbociclib plus
letrozole to week 14
(n = 68)
(n = 66)
(n = 3)
(n = 1)
(n = 1)
   Allocated
   Received treatment
   Ineligible but evaluable
    per ITT
   Withdrew consent to
    collect additional data
   Unwilling to continue
    with trial-related
    follow-up visits
   Allocated
   Received treatment
   Ineligible but evaluable
    per ITT
   Withdrew consent to
    collect additional data
   Unwilling to continue
    with trial-related
    follow-up visits
   Allocated
   Received treatment
   Ineligible but evaluable
    per ITT
   Withdrew consent to
    collect additional data
   Unwilling to continue
    with trial-related
    follow-up visits
   Allocated
   Received treatment
   Ineligible but evaluable
    per ITT
   Withdrew consent to
    collect additional data
   Unwilling to continue
    with trial-related
    follow-up visits
Group C: Palbociclib to week 2,
followed by palbociclib plus
letrozole to week 14
(n = 69)
(n = 69)
(n = 0)
(n = 0)
(n = 2)
Group D: Palbociclib plus
letrozole to week 14
(n = 67)
(n = 66)
(n = 0)
(n = 0)
(n = 1)
(n = 61)
(n = 1)
(n = 7)
   Evaluable clinical response
   Ultrasound measurement
    not evaluable
   Ultrasound not conducted
(n = 63)
(n = 0)
(n = 5)
   Evaluable clinical response
   Ultrasound measurement
    not evaluable
   Ultrasound not conducted
(n = 93)
(n = 0)
(n = 10)
   Evaluable clinical response
   Ultrasound measurement
    not evaluable
   Ultrasound not conducted
   Evaluable clinical response
   Ultrasound measurement
    not evaluable
   Ultrasound not conducted
(n = 62)
(n = 0)
(n = 5)
(n = 40)
(n = 3)
(n = 20)
(n = 5)
(n = 65)
(n = 3)
(n = 29)
(n = 6)
   Evaluable Ki-67 response
   Baseline not available
   Week 14 not available
   Baseline and week 14
    not available
   Evaluable Ki-67 response
   Baseline not available
   Week 14 not available
   Baseline and week 14
    not available
   Evaluable Ki-67 response
   Baseline not available
   Week 14 not available
   Baseline and week 14
    not available
(n = 47)
(n = 2)
(n = 17)
(n = 3)
   Evaluable Ki-67 response
   Baseline not available
   Week 14 not available
   Baseline and week 14
    not available
(n = 38)
(n = 4)
(n = 20)
(n = 5)
FIG 1. CONSORT diagram. ITT, intention to treat.
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(49.5%) of 93 patients achieved a complete or partial re-
sponse compared with 101 (54.4%) of 186 patients with
palbociclib plus letrozole (B + C + D). There was no evi-
dence that the inclusion of palbociclib changed clinical
response as measured by ultrasound (P = .20).
Log-fold changes in Ki-67 were available for 190 patients
(61.9%; Fig 2 and Table 2). Reasons for nonavailability of
paired Ki-67 results included missing and unevaluable
samples (Data Supplement) with histologic type and geo-
graphical region the only baseline characteristics differen-
tiating availability. Median log-fold change in Ki-67 between
baseline and EoT was 22.2 (IQR, 23.4 to 21.0) in the
letrozole group (A) compared with24.1 (IQR,25.0 to22.8;
one-sided P , .001) in palbociclib plus letrozole groups
(B + C + D). This corresponds to a geometric mean change
of 288.5% (95% CI, 292.3% to 282.9%) compared
with 297.4% (95% CI, 298.1% to 296.4%). The geo-
metric mean ratio was 0.16 (95% CI, 0.13 to 0.18; P ,
.001). CCCA was observed in 38 (58.5%) of 65 patients
in the letrozole group (A) compared with 113 (90.4%) of
125 in palbociclib plus letrozole groups (B + C + D; odds
ratio, 6.83; 95% CI, 3.12 to 14.98; P , .001).
Between baseline and week 2 there was a median log-
fold change in Ki-67 with letrozole alone (A + B) of 21.3
(IQR, 22.9 to 20.7) compared with 23.1 (IQR, 24.1
to21.5) in palbociclib alone (C; P, .001). Median log-fold
change in Ki-67 at week 2 with palbociclib plus letrozole
(D) was23.9 (IQR,24.7 to22.7; P, .001) compared with
groups who received letrozole alone for the ﬁrst 2 weeks
(A+B), and there was no signiﬁcant difference between
TABLE 1. Baseline Demographic and Clinical Characteristics by Randomized Treatment Group
Characteristic
Letrozole Alone
Letrozole + Palbociclib
From Week 2
Palbociclib + Letrozole
From Week 2
Palbociclib +
Letrozole
Palbociclib + Letrozole
Regimen
Group A
(n = 103) Group B (n = 68) Group C (n = 69) Group D (n = 67)
Groups B, C and D
(n = 204)
Median age, years (IQR) 65.8 (59.4-72.0) 66.3 (60.4-72.5) 63.5 (59.3-70.5) 63.8 (58.5-69.1) 64.4 (59.5-71.1)
Recruitment region
United Kingdom 56 (42.4) 37 (54.4) 37 (53.6) 36 (53.7) 110 (53.9)
North America 47 (45.6) 31 (45.6) 32 (46.4) 31 (46.3) 94 (46.1)
Tumor grade
Low 13 (12.6) 6 (8.8) 4 (5.8) 9 (13.4) 19 (9.3)
Intermediate 70 (68.0) 54 (79.4) 52 (75.4) 51 (76.1) 157 (77.0)
High 19 (18.5) 7 (10.3) 13 (18.8) 7 (10.5) 27 (13.2)
Not known 1 (1.0) 1 (1.5) 0 (0.0) 0 (0.0) 1 (0.5)
Histologic type
Ductal 74 (71.8) 49 (72.1) 46 (66.7) 45 (67.2) 140 (68.7)
Lobular 24 (23.3) 14 (20.6) 19 (27.5) 18 (26.9) 51 (25.0)
Mixed ductal and lobular 4 (3.9) 1 (1.5) 4 (5.8) 2 (3.0) 7 (3.4)
Mucinous 1 (1.0) 4 (5.9) 0 (0.0) 2 (3.0) 6 (2.9)
ER status
Positive 103 (100.0) 68 (100.0) 69 (100.0) 67 (100.0) 204 (100.0)
PgR status
Positive 74 (71.8) 47 (69.1) 41 (59.4) 53 (79.1) 141 (69.1)
Negative 15 (14.6) 10 (14.7) 15 (21.7) 7 (10.5) 32 (15.7)
Not determined 14 (13.7) 11 (16.2) 13 (18.8) 7 (10.5) 31 (15.2)
Surgical intent at baseline
Partial mastectomy/
lumpectomy
61 (59.2) 45 (66.2) 40 (58.0) 39 (58.2) 124 (60.8)
Total or modiﬁed radical
mastectomy
39 (37.9) 20 (29.4) 25 (36.2) 24 (35.8) 69 (33.8)
Missing 3 (2.9) 3 (4.4) 4 (5.8) 4 (6.0) 11 (5.4)
NOTE. Data are presented as No. (%) unless otherwise noted. See the Data Supplement (Results) for information on the associations between baseline
characteristics and the availability of Ki-67 results.
Abbreviations: ER, estrogen receptor; IQR, interquartile range; PgR, progesterone receptor.
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FIG 2. (A) Waterfall plot of log-fold change and
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and the end of treatment. Five patients had
a percentage increase greater than 125%. (B)
Spaghetti plots of individual trajectories of Ki-67
by randomized treatment group.
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palbociclib alone (C) and palbociclib plus letrozole (D; P =
.06). At week 2, CCCA was more common with palbociclib
plus letrozole than with palbociclib alone [D: 47 (89%) of 53
patients; 95% CI, 76% to 96% v C: 44 (72%) of 61 patients;
95% CI, 59% to 82%; P = .04]. Between week 2 and week
14, there was a median log-fold change in Ki-67 of 20.1
(IQR, 21.1 to 0.4) with letrozole alone (A) compared
with22.1 (IQR,23.5 to21.3; P, .001),20.4 (IQR,22.1
to 0.0; P = .12), and 0.0 (IQR, 20.1 to 0.9; P = .08) in
groups B, C, and D, respectively.
pCR in the breast occurred infrequently and there was
no evidence of a difference between letrozole [A; one
(1.1%) of 87 patients; 95% CI, 0.0 to 6.2) compared with
palbociclib plus letrozole [B + C + D; six (3.3%) of 180
patients; 95% CI, 1.2% to 7.1%; P = .43). pCR in breast,
axillary lymph nodes, and nonaxillary sentinel nodes
were found in two (1.1%) of 180 patients (95% CI, 0.0%
to 4.0%; P = 1.00) who received palbociclib plus
letrozole (B + C + D). There was no difference in the
proportion of patients whose intended surgery changed
from mastectomy at baseline to breast conservation at
week 14 with letrozole [A; 13 (14.1%) of 92 patients;
95% CI: 7.7% to 23.0%] compared with palbociclib plus
letrozole [B + C + D; 25 (14.1%) of 177 patients; 95% CI,
9.4% to 20.1%; P = 1.00].
Apoptosis, as measured by c-PARP, was a prespeciﬁed
exploratory biomarker with paired data available for 146
patients ((47.6%; Fig 3 and Table 2). Other prespeciﬁed
exploratory biomarkers are under analysis but not yet
available to report. The log-fold change in c-PARP between
baseline and EoT was 20.42 (IQR, 20.99 to 0.20) with
letrozole (A) compared with 20.80 (IQR, 21.35 to 20.29;
one-sided P, .001) with palbociclib plus letrozole (B + C +
D). Post hoc analyses found that at week 2 there was
a median log-fold change in c-PARP with letrozole (A + B)
of20.1 (IQR,20.6 to 0.2) compared with20.3 (IQR,20.8
to 20.1) with palbociclib (C; P = .004). Median log-fold
change in c-PARP at week 2 with palbociclib plus letrozole
(D) was 20.5 (IQR, 20.7 to 0.0) compared with letrozole
(A + B; P = .07), and there was no evidence of a difference
between palbociclib (C) versus palbociclib plus letrozole (D;
P = .47). Between week 2 and week 14, there was amedian
log-fold change in c-PARP of20.3 (IQR,20.7 to 0.0) with
letrozole (A) compared with 20.6 (IQR, 21.2 to 20.3;
P = .09), 20.3 (IQR, 21.0 to 0.1; P = .72), and 20.3
(IQR, 20.7 to 0.1; P = .82) in groups B, C, and D, re-
spectively. Any-grade adverse event (AE), irrespective of
the relationship to the study treatment, was reported in 91%
of patients with letrozole (A) and 99% of patients with
palbociclib plus letrozole (B + C + D). The majority of AEs
were grade 1 or 2 (91%). Grade 3 or greater AEs were
reported in 17% of patients with letrozole (A) and in 50%
of those in palbociclib plus letrozole groups (B + C + D;
P , .001; Table 3). In total, eight patients in palbociclib
plus letrozole groups (B + C + D) experienced 10 grade 4 or
5 AEs. Of these, one patient experienced a grade 5 acute
respiratory distress syndrome which was considered to be
unrelated to letrozole or palbociclib.
DISCUSSION
PALLET is the largest randomized trial of a CDK4/6 in-
hibitor in the neoadjuvant setting and demonstrates that
the addition of palbociclib to letrozole markedly enhanced
the suppression of malignant cell proliferation as assessed
by Ki-67. In addition, there was a signiﬁcant increase in
the number of patients who achieved CCCA in their tumor
after 14 weeks of combination therapy compared with
letrozole alone (90% v 59%). Although the suppression of
Ki-67 in the ﬁrst 2 weeks by palbociclib alone was sig-
niﬁcantly greater than by letrozole alone, the combination
palbociclib plus letrozole enhanced the proportion of
patients who achieved CCCA. In terms of toxicity, PALLET
detected no new signals with the addition of palbociclib in
patients with early-stage primary BC.
The lack of difference in clinical response rate (54.3% v
49.5%) is perhaps not a surprise given the cytostatic nature
of endocrine-based therapies in contrast to similar neo-
adjuvant trials using cytotoxic chemotherapies in triple-
negative BC or targeted combinations in HER2-positive
BC.18 In slower growing ER-positive tumors, therapies with
a predominantly antiproliferative effect will yield a slower
reduction in tumor size,19 especially over a short timeframe
of 14 weeks. When using primary endocrine therapy to
downstage ER-positive BC, maximal tumor shrinkage may
take at least 9 to 12 months.20 We also demonstrate for the
ﬁrst time to our knowledge—using c-PARP expression as
a biomarker—that unlike chemotherapy, wherein apoptosis
increases in addition to an antiproliferative effect,21 CDK4/6
therapy in combination with an AI produces a greater
suppression—not an increase—in apoptosis compared with
endocrine therapy alone. Measurement of c-PARP is only
one of a number of approaches to assessing apoptosis in situ.
It is notable that the decrease observed in the AI alone arm of
PALLET is similar to that observed when using the terminal
deoxynucleotidyl transferase dUTP nick end labeling
method in the IMPACT trial.22 This reduction in cell death
could also explain why overall tumor volume—that is,
clinical response—as determined by ultrasound did not
substantially change, nor did the surgical breast con-
servation rate, despite the markedly enhanced anti-
proliferative effect. Indeed, these data are consistent
with the PALOMA-2 study (ClinicalTrials.gov identiﬁer:
NCT01740427) in advanced BC in which the greatest
clinical impact was observed in progression-free survival
(hazard ratio, 0.58), rather than the best objective response
rate (ORR; 55% v 44%).6,8 Similarly, ORR with abemaciclib
plus AI in the MONARCH-3 trial was 59% versus 44% with
AI alone,23 and with ribociclib plus AI in the MONALEESA-2
trial ORR was 52.7% versus 37.1% with AI alone,24 yet
both studies also had highly signiﬁcant improvements in
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progression-free survival (hazard ratio, 0.54 and 0.57,
respectively). In early BC, it remains to be seen whether the
antiproliferative differences observed in the PALLET trial,
despite the lack of change in ORR in the neoadjuvant
setting, will translate into an effect on time to recurrence in
ongoing adjuvant studies.
Previous studies of neoadjuvant endocrine therapy have
also demonstrated that suppression of Ki-67, rather than
clinical response, is a better indicator of therapeutic activity
in ER-positive early BC. In the IMPACT trial, no difference in
clinical response rate was observed between anastrozole,
tamoxifen, or the combination (37% v 36% v 39%)25 after
3 months of therapy in 330 patients. However, signiﬁcantly
greater suppression of Ki-67 was reported for anastrozole
compared with tamoxifen at 12 weeks (81.6% v 61.9%).13,26
These differences in Ki-67 suppression were paralleled by
the greater beneﬁt from anastrozole versus tamoxifen or the
combination of anastrozole and tamoxifen in the ATAC
trial.27 Furthermore, the log-fold reduction in Ki-67 in
IMPACT was a predictor of subsequent RFS in the
adjuvant setting.13 Similarly, the greater suppression of
Ki-67 by letrozole than tamoxifen in P02428 paralleled
the greater improvement in RFS with letrozole in the anal-
ogous BIG1-98 adjuvant trial (ClinicalTrials.gov identiﬁer:
NCT00004205).29 When the different AIs were compared
in Z1031 (ClinicalTrials.gov identiﬁer: NCT00265759),14
the lack of difference in Ki-67 suppression was sup-
ported by similar RFS between groups in the adjuvant
studiesMA-27 (ClinicalTrials.gov identiﬁer: NCT00066573)30
and FACE (ClinicalTrials.gov identiﬁer: NCT00248170).31
More recently, the large United Kingdom POETIC trial
(ClinicalTrials.gov identiﬁer: NCT02338310) conﬁrmed that
the lack of suppression of Ki-67 after 2 weeks of preoperative
AI predicted for a signiﬁcantly worse 5-year RFS.32 CDK4/6
inhibitors restrict passage through the cell cycle and, like
endocrine agents, are therefore antiproliferative. However,
whether the lack of Ki-67 suppression after neoadjuvant
TABLE 3. Most Frequently Occurring Adverse Events
MedDRA-Coded AE Preferred Term
Letrozole Alone Palbociclib + Letrozole Regimen
Group A (n = 100) Groups B + C + D (n = 201)
Any Grade Grade ‡ 3 Any Grade Grade ‡ 3
Fatigue 41 (41.0) 0 (0.0) 117 (58.2) 4 (2.0)
Neutrophil count decreased 2 (2.0) 0 (0.0) 110 (54.7) 82 (40.8)
Hot ﬂush 40 (40.0) 0 (0.0) 54 (26.9) 0 (0.0)
Nausea 18 (18.0) 0 (0.0) 50 (24.9) 0 (0.0)
Arthralgia 26 (26.0) 0 (0.0) 37 (18.4) 1 (0.5)
Headache 21 (21.0) 0 (0.0) 37 (18.4) 0 (0.0)
WBC count decreased 1 (1.0) 0 (0.0) 49 (24.4) 12 (6.0)
Diarrhea 14 (14.0) 1 (1.0) 33 (16.4) 2 (1.0)
Constipation 10 (10.0) 0 (0.0) 26 (12.9) 0 (0.0)
Breast pain 12 (12.0) 0 (0.0) 20 (10.0) 1 (0.5)
Platelet count decreased 0 (0.0) 0 (0.0) 31 (15.4) 0 (0.0)
Dizziness 7 (7.0) 0 (0.0) 24 (11.9) 0 (0.0)
Alanine aminotransferase increased 7 (7.0) 0 (0.0) 23 (11.4) 8 (4.0)
Alopecia 3 (3.0) 0 (0.0) 26 (12.9) 0 (0.0)
Hypertension 11 (11.0) 8 (8.0) 15 (7.5) 9 (4.5)
Cough 3 (3.0) 0 (0.0) 21 (10.4) 0 (0.0)
Anemia 3 (3.0) 0 (0.0) 20 (10.0) 0 (0.0)
Epistaxis 2 (2.0) 0 (0.0) 20 (10.0) 0 (0.0)
Stomatitis 0 (0.0) 0 (0.0) 20 (10.0) 2 (1.0)
Depression 10 (10.0) 0 (0.0) 9 (4.5) 0 (0.0)
Pain in extremity 10 (10.0) 1 (1.0) 9 (4.5) 0 (0.0)
Myalgia 11 (11.0) 0 (0.0) 8 (4.0) 0 (0.0)
NOTE. Data are presented as No. (%). Data are the number of patients experiencing any-grade or grade 3 or greater AEs as per MedDRA-preferred term
AEs. Sorted by most frequent AE of any grade occurring overall. Only AEs occurring in more than 10% of patients in group A or in the palbociclib plus letrozole
groups are reported. Percentages within group are based on the as-treated populations.
Abbreviation: AE, adverse event.
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CDK4/6 inhibitor therapy is similarly predictive remains
unconﬁrmed.
Suppression of Ki-67 in the ﬁrst 2 weeks by palbociclib
alone was signiﬁcantly greater than that by letrozole
alone, a ﬁnding also reported recently in the small,
phase II preoperative palbociclib trial (ClinicalTrials.
gov identiﬁer: NCT02008734).33 However, in the PAL-
LET trial, the four-group design demonstrated that the
palbociclib plus letrozole combination enhanced the
proportion of patients who achieved CCCA in the ﬁrst
2 weeks, and that the addition of the AI maximizes Ki-67
suppression.
In a previous small, phase II study (NeoPalAna; ClinicalTrials.
gov identiﬁer: NCT01723774) in 50 patients with ER-positive
early BC of different intrinsic subtypes, sequential biopsies
were taken in patients who were initiated on anastrozole for
4 weeks, followed by the addition of palbociclib to study the
additional change or decrease in Ki-67.34 Rates of CCCA
with palbociclib and anastrozole were signiﬁcantly higher
(87%) than with anastrozole alone (26%), and biomarker
analysis suggested that response to palbociclib occurred
independently of tumor grade, absence of progesterone
receptor expression, or mutation in p53, PIK3CA, or PTEN
genes, but was correlated with RB1 mutation status. Exten-
sive gene and protein expression analyses are being un-
dertaken in PALLET as exploratory end points. These will be
correlated with antiproliferative response and could yield
important information about predictive biomarkers for this
class of therapy in the early BC setting, which can be tested
in the adjuvant setting.
In NeoPalAna, it was reported that the antiproliferative
effect of palbociclib diminished rapidly after treatment
stopped in some patients, which suggests the need for
continued therapy.34 For this reason, in PALLET, we aimed
to ensure that the 14-week biopsy was taken during ex-
posure to drug therapy and excluded 2.6% of 14-week
samples as they fell outside the 48-hour window since the
last drug dose taken. In addition, 13.0% of patients had an
unevaluable sample which could reﬂect minimal cellularity
in the core biopsy. Studies to assess the correlation be-
tween the 14-week samples with cellularity and Ki-67 in the
excised surgical sample are ongoing.
In the only other randomized neoadjuvant trial of CDK4/6 in-
hibitors in ER-positive early BC (NeoMONARCH; ClinicalTrials.
gov identiﬁer: NCT02441946), 224 patients were randomly
assigned to either anastrozole, abemaciclib (Verzenio; Eli
Lilly, Indianapolis, IN), or the combination, with biopsies
taken at baseline, 2 weeks, and after 16 weeks of therapy.35
Combination abemaciclib plus anastrozole was associated
with a greater geometric mean decrease in Ki-67 at 2 weeks
(292.6% v 263.2%), with a signiﬁcant increase in CCCA
(66% v 14%). To date, biomarkers of response or re-
sistance to abemaciclib have not been identiﬁed, although
reports of induced histologic changes that are suggestive of
tumor differentiation and increased lymphocytic inﬁltration
were observed in some cases.35
The incomplete availability of biopsy samples could poten-
tially bias the biologic ﬁndings for Ki-67 and c-PARP. When
EoT biopsies were not taken (n = 38), this often occurred with
incomplete treatment (n = 29; 76%). Excluding these cases
could overstate the proportion who responded; however,
there were an approximately equal number of cases in which
Ki-67 was unevaluable as a result of scant tumor in the
biopsy. A similar level of Ki-67 suppression would be ex-
pected in these cases compared with the evaluable pop-
ulation and so would not be expected to bias our ﬁndings.
Other trials that featured Ki-67 as an end point have ob-
served similar evaluable proportions. In the NeoMONARCH
study, 138 (61.9%) of 223 patients were evaluable for Ki-67
compared with 190 (61.9%) of 307 in our trial. Analyses of
Ki-67 and c-PARP levels between baseline and week 2 and
from week 2 to EoT in PALLET were conducted post hoc
and did not adjust for multiple testing and so should be
cautiously interpreted. Nonetheless, such ﬁndings match
our expectations that the addition of palbociclib to letrozole
would increase the suppression of cell proliferation.
In conclusion, the PALLET trial demonstrated that the
addition of palbociclib to letrozole markedly enhanced the
suppression of malignant cell proliferation as measured by
Ki-67 expression, yet did not increase tumor shrinkage as
determined by clinical ultrasound. Correlating biomarkers
of antiproliferative response in the context of a randomized
neoadjuvant study will be important in determining which
patients may derive themost beneﬁt from CDK4/6 inhibitors
in ongoing adjuvant studies in early BC.
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